QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.896

Change

-0.01 (-0.09)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.24 (+0.88%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 109.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.28 (-0.05%)

USD 96.22B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.44 (+0.79%)

USD 91.00B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.85 (+0.78%)

USD 54.70B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.12 (+0.81%)

USD 52.21B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.45 (+0.46%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.01 (-0.10%)

USD 40.38B
0ZC:F Zscaler Inc

+1.24 (+0.81%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.65% 73% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.65% 70% C- 61% D-
Trailing 12 Months  
Capital Gain 16.47% 66% D+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.47% 62% D 58% F
Trailing 5 Years  
Capital Gain 80.73% 90% A- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.73% 90% A- 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.17% 81% B- 74% C
Dividend Return 12.17% 79% B- 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.06% 62% D 86% B+
Risk Adjusted Return 110.04% 99% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike